Conversations in Interventional Cardiology - Aortic Valve Replacement in Asymptomatic Severe Aortic Stenosis: A Systematic Review and Meta-Analysis

Overview

This discussion highlights emerging evidence in asymptomatic severe aortic stenosis, comparing SAVR/TAVR with clinical surveillance. Based on a recent JSCAI article, faculty review key findings suggesting improved survival and fewer cardiovascular or heart failure hospitalizations and strokes with AVR, and briefly outline the potential benefits and challenges of earlier intervention.

Read the article in JSCAI here.

Faculty

	Andrew M. Goldsweig, MD, MSc, FSCAI Moderator		Philippe Généreux, MD Presenting Author
	Islam Y. Elgendy, MD, FSCAI Panelist		Michael J. Reardon, MD Panelist

Acknowledgement of Commercial Support

This activity is supported by unrestricted educational grants from Edwards Lifesciences.

Learning objectives

At the end of this activity, participants should be able to:

Describe the role of SAVR/TAVR, compared to clinical surveillance, on clinical outcomes for patients with asymptomatic severe aortic stenosis.
Evaluate the potential benefits and challenges of performing AVR intervention in asymptomatic AS patients, considering the current guidance provided to physicians and the new available evidence.
Analyze the clinical outcomes of AVR versus CS in patients with asymptomatic severe AS based on data from randomized controlled trials (RCT) and meta-analysis findings, and evaluate the implications of recent systematic review and meta-analysis findings on the management strategies for asymptomatic severe AS.
Assess the benefits and challenges of AVR intervention in patients with asymptomatic severe AS using data provided in the recently published systematic review article.

Disclosures

Individuals in control of content reported the following relevant financial relationships with ineligible companies during the content development process for this activity. All relevant financial relationships were mitigated before the start of the activity.

Planner
Alexandra Lansky: Boston Scientific - speaker; Microport - speaker; Philips - Advisory Board.

Faculty
Islam Elgendy: No relevant financial relationships with ineligible companies.
Andrew Goldsweig: Abbott - consulting.
Philippe Généreux: Abbott - consulting, PI; Edwards Lifesciences - consulting, PI, advisor fees; Medtronic - consulting.
Michael Reardon: Abbott – consulting; Medtronic - speaker.

Reviewer
Nkechi Ijioma: No relevant financial relationships with ineligible companies.

Staff
Keondae Ervin, Kristen Perry, and Amanda Pettyjohn: No relevant financial relationships with ineligible companies.

Accredited Continuing Education Information

Accreditation Statement
The Society for Cardiovascular Angiography and Interventions (SCAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
SCAI designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 0.25 MOC points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABIM MOC credit.

Successful Completion
Watch the content and complete the evaluation to obtain credit.

SCAI's Independent Content

As a provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME), it is the Society’s policy to ensure balance, independence, objectivity, and scientific rigor in all its activities.

Planning Process
SCAI activities are developed by the SCAI Planners prior to and independent of commercial support. Members of the Publications Committee reviewed and approved this activity. If planners had relevant financial relationships, the agenda was peer reviewed by a member with no relevant financial relationships.

Mitigation of Relevant Financial Relationships
All participating planners, reviewers, faculty, and staff are required to disclose to SCAI any relevant financial relationships. SCAI identifies relevant financial relationships and mitigates them before the activity begins.

Content Validation Statement

SCAI accepts the following Content Validation Statements and expects all persons involved in its professional education activities to abide by these statements for clinical care recommendations. All clinical and pharmacological recommendations are based on evidence accepted within the medical profession as adequate jurisdiction for their indications and contradictions in patient care. All research referenced to support or justify patient care recommendations conforms to accepted standards of experimental design, data collection and analysis.

SCAI does not promote recommendations, treatment, or manners of practicing medicine that are not within the definition of accredited continuing education or known to have risks or dangers that outweigh the benefits or known to be ineffective in the treatment of patients.

SCAI actively promotes improvements in health care and NOT proprietary interests of an ineligible company.

SCAI's educational content is free of marketing or sales of products or services. Faculty will not actively promote or sell products or services that serve their professional or financial interests during accredited education. 

SCAI encourages faculty to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration (FDA), at first mention and where appropriate in the content.

Summary

Availability:

On-Demand

Access expires on Apr 30, 2029

Cost:

FREE

Credit Offered:

0.25 CME Credit

0.25 ABIM-MOC Point

0.25 Participation Credit